DOP2022000136A - Anticuerpos cd163 o proteínas de unión - Google Patents

Anticuerpos cd163 o proteínas de unión

Info

Publication number
DOP2022000136A
DOP2022000136A DO2022000136A DO2022000136A DOP2022000136A DO P2022000136 A DOP2022000136 A DO P2022000136A DO 2022000136 A DO2022000136 A DO 2022000136A DO 2022000136 A DO2022000136 A DO 2022000136A DO P2022000136 A DOP2022000136 A DO P2022000136A
Authority
DO
Dominican Republic
Prior art keywords
porcine
antigen
binds
amino acid
binding domain
Prior art date
Application number
DO2022000136A
Other languages
English (en)
Spanish (es)
Inventor
Owen Charles
Abdelaali Benchaoui Hafid
TAIT-BURKARD Christine
Original Assignee
Eco Animal Health Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eco Animal Health Ltd filed Critical Eco Animal Health Ltd
Publication of DOP2022000136A publication Critical patent/DOP2022000136A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DO2022000136A 2019-12-24 2022-06-23 Anticuerpos cd163 o proteínas de unión DOP2022000136A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1919294.7A GB201919294D0 (en) 2019-12-24 2019-12-24 Antibodies or binding proteins
PCT/GB2020/053370 WO2021130502A1 (en) 2019-12-24 2020-12-24 Cd163 antibodies or binding proteins

Publications (1)

Publication Number Publication Date
DOP2022000136A true DOP2022000136A (es) 2022-11-30

Family

ID=69322779

Family Applications (2)

Application Number Title Priority Date Filing Date
DO2022000136A DOP2022000136A (es) 2019-12-24 2022-06-23 Anticuerpos cd163 o proteínas de unión
DO2025000290A DOP2025000290A (es) 2019-12-24 2025-11-21 Anticuerpos cd163 o proteínas de unión

Family Applications After (1)

Application Number Title Priority Date Filing Date
DO2025000290A DOP2025000290A (es) 2019-12-24 2025-11-21 Anticuerpos cd163 o proteínas de unión

Country Status (13)

Country Link
US (1) US20230203185A1 (cg-RX-API-DMAC7.html)
EP (1) EP4081542A1 (cg-RX-API-DMAC7.html)
JP (1) JP7702952B2 (cg-RX-API-DMAC7.html)
KR (2) KR20260098023A (cg-RX-API-DMAC7.html)
CN (2) CN115151569B (cg-RX-API-DMAC7.html)
BR (1) BR112022012362A2 (cg-RX-API-DMAC7.html)
CL (1) CL2022001706A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022010294A2 (cg-RX-API-DMAC7.html)
DO (2) DOP2022000136A (cg-RX-API-DMAC7.html)
GB (1) GB201919294D0 (cg-RX-API-DMAC7.html)
MX (1) MX428622B (cg-RX-API-DMAC7.html)
PE (1) PE20230384A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021130502A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12098400B2 (en) * 2022-07-08 2024-09-24 Novo Nordisk A/S Highly potent ISVD compounds capable of substituting for FVIII(A)
GB202214979D0 (en) * 2022-10-11 2022-11-23 Eco Animal Health Ltd Binding protein
JP2026519901A (ja) * 2023-01-27 2026-06-19 ヴィーアイビー ヴィーゼットヴィー Cd163結合複合体
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN119569865B (zh) * 2024-12-20 2025-10-10 西北农林科技大学 一种防治猪繁殖与呼吸障碍综合征病毒感染的混合制剂及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076501A2 (en) * 2001-03-26 2002-10-03 Hemosol Inc. Blood cell production via activation of the hemoglobin scavenger receptor
NZ540194A (en) * 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US20160158368A1 (en) * 2014-10-31 2016-06-09 Therapure Biopharma Inc. Methods and compositions for the treatment of histiocytosis
HRP20240908T1 (hr) * 2015-08-06 2024-10-25 The Curators Of The University Of Missouri Svinja i stanice otporne na virus reproduktivnog i respiratornog sindroma svinja (prrsv) koje imaju modificirane cd163 gene
US11160260B2 (en) * 2018-04-17 2021-11-02 The Curators Of The University Of Missouri Methods for protecting porcine fetuses from infection with porcine reproductive and respiratory syndrome virus (PRRSV)

Also Published As

Publication number Publication date
JP2023508674A (ja) 2023-03-03
CO2022010294A2 (es) 2022-10-31
US20230203185A1 (en) 2023-06-29
PE20230384A1 (es) 2023-03-06
CN115151569A (zh) 2022-10-04
KR20260098023A (ko) 2026-06-25
BR112022012362A2 (pt) 2022-09-06
CN121873247A (zh) 2026-04-17
MX2022007957A (es) 2022-10-07
WO2021130502A1 (en) 2021-07-01
CL2022001706A1 (es) 2023-05-26
DOP2025000290A (es) 2026-02-26
KR20220119147A (ko) 2022-08-26
CA3162664A1 (en) 2021-07-01
MX428622B (es) 2025-11-13
CN115151569B (zh) 2026-05-01
EP4081542A1 (en) 2022-11-02
JP7702952B2 (ja) 2025-07-04
GB201919294D0 (en) 2020-02-05

Similar Documents

Publication Publication Date Title
CL2022001706A1 (es) Anticuerpos o proteínas de unión a cd163.
CR20210199A (es) Moléculas de unión a antígeno capaces de unirse al cúmulo de diferenciación 3 (cd3) y al cúmulo de diferenciación 137 (cd137) pero no simultáneamente
WO2021156490A3 (en) Corona virus binders
CR20200579A (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
AR109882A1 (es) Anticuerpos monoclonales neutralizantes anti-tl1a
DOP2023000130A (es) ANTICUERPOS MULTIESPECÍFICOS QUE TIENEN ESPECIFICIDAD PARA IL-4R e IL-31
IL299221A (en) Cd3 binding antibodies
HRP20241381T1 (hr) Nova anti-pd-1 protutijela
UY37694A (es) Dominios de unión a antígeno humanizados y métodos de uso
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
PE20251579A1 (es) Anticuerpos especificos para cd70 y sus usos
PE20120475A1 (es) Anticuerpos especificos para dkk-1
JP2015525795A5 (cg-RX-API-DMAC7.html)
PE20141433A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
PE20191031A1 (es) ANTICUERPOS ANTI-C1s Y METODOS DE USO DE LOS MISMOS
DOP2018000234A (es) Anticuerpos anti-basigin humanizados y uso de los mismos
PE20230839A1 (es) Agentes de union a lair-1 y metodos para su uso
EA201792329A1 (ru) Способ мономеризации рекомбинантных молекул антител
PE20230306A1 (es) Anticuerpos que se dirigen a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso
CL2021002792A1 (es) Anticuerpo monoclonal que se une específicamente a gitr
WO2020257789A3 (en) Anti-tim-3 antibodies
IL250289B2 (en) Antibodies against angiopoietin-like 4 and methods of use
AR087485A1 (es) Anticuerpos de union a fosforilcolina (pc) y/o conjugados de pc
MX2022006728A (es) Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario.
BR112022006364A2 (pt) Anticorpo híbrido